KLRS Hisse Senedi Fiyat Grafiği
KLRS Kazanmak
Kalaris Therapeutics Inc
$3.97
0.76%
$0.03
Kapanışta: Aug 11, 16:00:00 GMT-4
$4.04
1.76%
$0.06
Sonrası Piyasa: Aug 11, 20:00:00 GMT-4
Geri
Kalaris Therapeutics Inc (KLRS) Kazanmak
Son Finansal Sonuçlar: Q1 '26
Raporlandı: 2026-05-12
Geçmiş Kazançlar
Dönemlik
Yıllık
EPS
Gelir
Earnings FAQ
KLRS'ün son EPS'si beklentilerle karşılaştırıldığında nasıldı?
Kalaris Therapeutics Inc KLRS'ün son çeyrekteki geliri nasıl performans gösterdi?
Kalaris Therapeutics Inc'in gelir tahmini nedir?
Kalaris Therapeutics Inc'in kazanç kalite puanı nedir?
Kalaris Therapeutics Inc kazançlarını ne zaman rapor eder?
Kalaris Therapeutics Inc'in beklenen kazançları nelerdir?
Kalaris Therapeutics Inc kazanç beklentilerini aştı mı?
Önemli İstatistikler
Önceki Kapanış
$3.94
Açılış fiyatı
$3.95
Günün Aralığı
$3.94 - $4.04
52 haftalık aralık
$2.14 - $11.88
İşlem hacmi
27.3K
Ort.Hacim
212.8K
Dividend yield
--
EPS (TTM)
-2.21
Piyasa Değeri
$96.1M
KLRS nedir?
Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. The company is headquartered in Berkeley Heights, New Jersey and currently employs 20 full-time employees. The company went IPO on 2020-07-30. The firm is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
